← Back to Search

High-Risk Screening for Lung Cancer

Waitlist Available
Led By Melissa New, MD
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult 40-82 yrs of age
Calculated 6 yr lung cancer risk >1.5% for patients 40-77 years of age or >4% for patients 78-82 years of age
Screening 3 weeks
Treatment Varies
Follow Up duration of the study, up to 3 years
Awards & highlights

Study Summary

This trial is testing a new screening method for people who are at high risk for lung cancer, but don't qualify for current screening guidelines.

Eligible Conditions
  • Lung Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
You are between 40 and 82 years old.
Your calculated risk of developing lung cancer in the next 6 years is higher than a certain percentage for your age group.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~duration of the study, up to 3 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and duration of the study, up to 3 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Economic Outcomes
Lung Cancer Screening
Medical Outcomes

Trial Design

1Treatment groups
Experimental Treatment
Group I: ScreeningExperimental Treatment1 Intervention
Subjects will undergo a low dose non contrast CT chest for lung cancer screening.
First Studied
Drug Approval Stage
How many patients have taken this drug

Find a Location

Who is running the clinical trial?

University of Colorado, DenverLead Sponsor
1,732 Previous Clinical Trials
2,143,500 Total Patients Enrolled
Melissa New, MDPrincipal InvestigatorUniversity of Colorado, Denver

Media Library

Screening Clinical Trial Eligibility Overview. Trial Name: NCT03683940 — N/A
Lung Cancer Research Study Groups: Screening
Lung Cancer Clinical Trial 2023: Screening Highlights & Side Effects. Trial Name: NCT03683940 — N/A
Screening 2023 Treatment Timeline for Medical Study. Trial Name: NCT03683940 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~6 spots leftby Apr 2025